Kanna: Nootropic Benefits, Uses, Dosage, & Side Effects

Kanna (Sceletium tortuosum) is a psychoactive succulent from South Africa whose best-known alkaloid, mesembrine, blocks the serotonin transporter, the target of SSRI antidepressants, while a second alkaloid, mesembrenone, also inhibits the enzyme phosphodiesterase-4 (PDE4) in lab assays.⁽¹⁾ In its best-studied form, the standardized extract Zembrin, a single 25 mg dose reduced the amygdala’s reaction to fearful faces during a low-demand task in 16 healthy adults scanned 2 hours later.⁽²⁾

A 3-month trial in 37 healthy adults found no differences from placebo in heart rhythm (ECG) or physical examination and no significant changes in blood tests at 8 or 25 mg per day,⁽³⁾ while a 2023 meta-analysis of four small trials found no difference from placebo in anxiety worsening and called the anxiety evidence inconclusive.⁽⁴⁾ Kanna is not a substitute for prescribed treatment, and combining it with antidepressants would add to their serotonin effects (inferred from its mechanism; see Contraindications).

What is Kanna?

Kanna is the common name of Sceletium tortuosum (also classified as Mesembryanthemum tortuosum), a psychoactive succulent plant endemic to South Africa.⁽²⁾ It grows in the Karoo, in the triangle of the Montagu, Aberdeen and Namaqualand districts.⁽⁵⁾

Its other names are kougoed and kauwgoed, Afrikaans for “chew stuff”, and channa;⁽⁵⁾ Canna, the spelling recorded during Simon van der Stel’s 1685 expedition to Namaqualand, is an old spelling of kanna.⁽⁶⁾ Misspellings such as kana and kannna refer to the same plant.

San and Khoikhoi people have a long history of using it as a masticatory and medicine,⁽²⁾ traditionally for its sedative, anxiolytic, and euphoric effects. The plant was crushed, fermented and chewed, brewed as a tea, and occasionally taken as a snuff or smoked; Nama people also chewed it to relieve toothache, abdominal pain and hunger.⁽⁶⁾

Kanna contains mesembrine alkaloids, which act as serotonin reuptake inhibitors (SRI): they slow the removal of serotonin, a mood-regulating messenger, from the gaps between nerve cells. Kanna at a glance:

• Plant: Sceletium tortuosum, a low succulent; the alkaloids sit in the leaves.
• Class: herbal supplement with serotonergic alkaloids, one of the natural nootropics.
• Main alkaloids and targets: mesembrine, mesembrenone, mesembrenol and mesembranol; serotonin transporter and PDE4.
• Forms sold: dried plant powder, fermented kougoed, tea, standardized extract capsules (Zembrin), high-mesembrine extracts, tinctures and gummies.
• Human-tested dose: 8 to 50 mg of Zembrin extract per day; effects measured 30 minutes to 2 hours after a dose.
• Onset and duration: not measured in people; users report onset within about 15 to 60 minutes and effects lasting 2 to 4 hours (anecdotal).
• Rat doses: 25 and 50 mg/kg, estimated at about 284 and 568 mg for a 70 kg adult; not tested in people and 11 to 23 times the 25 mg trial dose (see Dosage).
• Half-life in humans: not established in published studies.
• Legal status: sold as a dietary supplement in most of the US (Louisiana restricts other forms); the UK Psychoactive Substances Act 2016 bans supplying any psychoactive substance for its psychoactive effect (see Is Kanna Legal?).
• Main risk: added serotonin effects with antidepressants and other serotonergic drugs (see Contraindications).

What Active Compounds are Present in Kanna?

A 25 mg dose of Zembrin, the standardized kanna extract used in human trials, contains about 100 micrograms (µg) of total mesembrine alkaloids,⁽⁵⁾ and with mesembrine at 13.2% of them (mesembrenone 47.9%, mesembrenol 32%, mesembranol 6.8%), that is roughly 13 µg of mesembrine per dose (100 µg x 0.132 = 13.2 µg).⁽⁷⁾ Human trials have tested the whole extract, not isolated mesembrine.

Mesembrine, the plant’s best-known alkaloid, bound the serotonin transporter with a Ki of 1.4 nM, against 27 nM for mesembrenone and 62 nM for mesembrenol (Ki is the concentration that occupies half the binding sites; lower means stronger binding).⁽¹⁾ In the leaves, mesembrine was the most abundant alkaloid, and none of these alkaloids was detected in the stems.⁽⁶⁾ Mesembrine is PubChem CID 394162, formula C17H23NO3, CAS number 24880-43-1.⁽⁸⁾ Its other lab targets:

1. PDE4 and cAMP: mesembrenone inhibited the PDE4B enzyme at an IC50 (concentration giving half inhibition) of 470 nM, 17 times more potently than mesembrine (7,800 nM).⁽¹⁾ PDE4 breaks down cAMP, a messenger molecule inside nerve cells, so blocking it raises cAMP.
2. GABA, opioid and other receptors: the whole extract also bound GABA, opioid, cholecystokinin and melatonin-1 receptors, but only at concentrations 30 to 150 times higher than it needed at the serotonin transporter, and the three purified alkaloids had little effect at GABA-A and GABA-B receptors.⁽¹⁾
3. Dopamine and noradrenaline: mesembrine inhibited their reuptake only at much higher concentrations than serotonin reuptake.⁽⁶⁾

Mesembrine is the stronger serotonin-transporter binder (1.4 versus 27 nM), while mesembrenone is the stronger PDE4 inhibitor and the larger share of Zembrin, so a high-mesembrine extract and Zembrin are different products. If enough alkaloid reaches the brain, serotonin reuptake inhibition (the SSRI mechanism) and PDE4 inhibition (which supports memory formation in animal models) would fit the calmer stress responses and executive-function gains seen in trials; this link is inferred, not measured.

Kanna Extract: Benefits and Considerations

Kanna extract is a concentrated preparation of Sceletium tortuosum standardized to a stated alkaloid content; Zembrin, the extract used in the human trials, is a hydro-ethanolic extract standardized to 0.35% to 0.45% total alkaloids, with mesembrenone and mesembrenol at 60% or more and mesembrine under 20%.⁽⁹⁾

Raw plant varies far more: total alkaloids in dried Sceletium tortuosum range from 0.05% to 2.3%.⁽⁶⁾ At that range, 1 g of dried plant holds 0.5 to 23 mg of alkaloids, which is 5 to 230 times the roughly 0.1 mg in a 25 mg Zembrin dose (1,000 mg x 0.05% = 0.5 mg; 1,000 mg x 2.3% = 23 mg). Two plant products of the same weight can differ up to 46-fold in alkaloid content (2.3% / 0.05% = 46).

Extract types and forms:

• Standardized hydro-ethanolic extract (Zembrin): the only form with trial efficacy and safety data; labels state mg of extract, and 25 mg is the most-tested amount.
• High-mesembrine extracts: one proprietary extract, Trimesemine, contains 70% mesembrine by weight;⁽⁵⁾ it has not been tested in the human trials.
• Fermented kougoed: traditional crushing and fermenting changes the alkaloids; in a controlled fermentation, mesembrine fell from 1.33% to 0.05% of the material by day 10 (a 96.2% relative drop) while Δ7-mesembrenone rose to 0.11%.⁽¹⁰⁾ Users describe its effects and side effects as stronger (anecdotal).
• Dried plant powder and tea: the least predictable form; users more often report digestive discomfort with raw plant (anecdotal).
• Gummies, vape extracts and snorting powders: sold by online shops in these forms;⁽¹¹⁾ none of them was the form used in trials.

What a good label shows: the plant part, the extract type, the total alkaloid percentage and, ideally, the amount of each alkaloid per serving. A product that lists only “kanna 500 mg”, or only a brand name or product code, gives no way to compare its strength with the doses used in trials.

Strength and route: a high-alkaloid extract delivers more alkaloid per milligram, so effects and side effects per milligram would be stronger than with dried plant (inferred). Holding kanna in the mouth is the traditional route; whether it raises absorption is not established.

Extract Storage and Shelf Life:
In solution, mesembrine converted to other alkaloids under sunlight, and no conversion occurred in the dark,⁽¹⁰⁾ so kanna keeps best in an airtight, dark container away from heat and moisture; the label’s expiry date sets the shelf life.

What Are the Nootropic Effects of Kanna?

In single small trials in healthy adults, kanna lowered anxiety before a simulated public speech, improved executive function over 3 weeks and improved complex reaction after 8 days (borderline, p = 0.05); memory and mood scores did not change, and a pooled analysis judged the anxiety evidence inconclusive (see the anxiety section). Side effects in the same trials are under Side Effects. The human studies are small, short and used only the Zembrin extract.⁽¹¹⁾

Human trials of kanna extract (Zembrin) in healthy adults (crossover means each person took kanna and placebo in turn):

Could Kanna be Used to Treat Anxiety and Stress Disorders?

Kanna has reduced laboratory-induced anxiety in healthy volunteers but has not been tested in people with an anxiety disorder. A 2023 meta-analysis pooled four small 25 mg trials (117 participants), the imaging, cognition, reaction and Reay stress studies in the table, of which only the Reay paper set out to measure anxiety; it found no difference from placebo in the risk of anxiety worsening (risk ratio 1.01, 95% CI 0.56 to 1.83; p = 0.98; a risk ratio of 1.0 means equal risk in both groups) and concluded that kanna cannot be recommended as an anxiety therapy on current evidence.⁽⁴⁾

In the public-speech study, scores on the state anxiety scale (STAI, a 20-item questionnaire) rose 3.38 points from baseline to just before the speech with kanna (30.58 to 33.96) and 9.05 points with placebo (35.38 to 44.43), a gap of 5.67 points. The placebo group started higher, and the baseline-adjusted difference before the speech was significant (p = 0.009; effect size d = 1.01, meaning the groups differed by about one standard deviation). After the speech, scores were 37.82 with kanna and 35.88 with placebo, and heart rate rose during the speech with placebo but not with kanna.⁽¹²⁾

In the 6-week trial in adults aged 50 to 80, scores on the Hamilton Anxiety Rating Scale (HAM-A, a clinician-rated anxiety scale) fell in the 50 mg group compared with that group’s own starting score (p = 0.03); this was a change within the group, not a difference from placebo.⁽¹⁵⁾ No trial has enrolled people with social anxiety, generalized anxiety or panic disorder, so anyone with an anxiety disorder, especially on prescribed medicine, should discuss kanna with a doctor.

Does Kanna Have Potential as an Antidepressant or Mood Stabilizer?

Kanna has antidepressant-like effects in rats and in published case reports, but the controlled human trials enrolled people without depression; the 3-week cognition trial, for example, excluded anyone scoring 8 or more on the Hamilton depression scale.⁽¹³⁾

In Flinders Sensitive Line rats, a genetic model of depression, single oral doses of Zembrin at 25 and 50 mg/kg reduced immobility in the forced swim test, and 50 mg/kg matched the antidepressant escitalopram at 5 mg/kg.⁽⁷⁾ In another rat study, an alkaloid-enriched kanna fraction had antidepressant-like effects but also caused ataxia, a loss of coordination.⁽¹⁶⁾ The human-equivalent amounts of these rat doses are in the Dosage section.

Published case reports describe patients with depression or dysthymia who were given 50 mg Sceletium tablets daily; one doubled to two 50 mg tablets before exams, and one reported a transient rise in anxiety lasting up to 3 hours that was gone after the first week.⁽⁶⁾ In healthy adults whose Hamilton depression scores were already near the bottom of the scale, scores fell from 1.67 to 1.22 points over 3 weeks with kanna (26.9%) and from 1.95 to 1.68 with placebo (13.8%), a difference that was not statistically significant.⁽¹³⁾

No study has tested kanna as a mood stabilizer; as a serotonin-reuptake blocker it would be expected to share antidepressants’ risk of triggering mania in people with bipolar disorder (inferred from the mechanism). Depression needs medical care; see nootropics for depression for other options and their evidence.

Can Kanna Improve Memory and Learning?

Kanna has not improved memory in the trials that measured it: after 3 weeks at 25 mg per day, composite, verbal and visual memory scores did not differ from placebo,⁽¹³⁾ and a single 25 mg dose did not change word recall or other outcomes in a multitasking study of 20 young adults.⁽¹²⁾

Whether kanna’s PDE4 activity is strong enough in people to change learning is inferred, not shown.

How Does Kanna Support Mental Clarity and Focus?

Kanna’s clearest cognitive result is in executive function, the planning and switching skills behind focus: in 21 adults (mean age 54.6), 3 weeks at 25 mg per day improved cognitive flexibility (p = 0.022) and executive function (p = 0.032) in a three-way comparison of baseline, kanna and placebo phases, with large effect sizes (Cohen’s d 1.47 and 1.49; a d above 0.8 is conventionally called large).⁽¹³⁾

In 60 recreationally trained adults aged 20 to 35, 8 days at 25 mg per day increased successful hits in a visual reaction task done while announcing a 5-digit number (change of 3.63 versus 0.23 hits; p = 0.05) and improved reactive agility that required a decision (p < 0.001), but did not change simple reaction time, visual tracking, alertness or energy.⁽¹⁴⁾

If calmer stress responses carry over to focus under pressure, that would fit the reaction-under-load result (inferred). None of the trials enrolled people with ADHD, and kanna is not a stimulant substitute.

Does Kanna Help With Sleep?

Kanna has not been tested as a sleep aid, but two trials recorded sleep: in the 3-week trial, the sleep-onset difficulty rating fell from 0.76 to 0.43 during the kanna phase (p = 0.049, compared with its own baseline, not with placebo),⁽¹³⁾ and in the 3-month safety trial 1 of 12 people on 25 mg noted better sleep, while insomnia was reported once in each kanna group and never with placebo.⁽³⁾

Users commonly report that kanna feels relaxing at low amounts and more stimulating at higher amounts, and that late-day use can disturb sleep; these reports are anecdotal.

Does Kanna Have Hallucinogenic Effects?

Kanna can produce a high at large doses: taken in intoxicating amounts it can cause euphoria, first with stimulation and then sedation, but the plant is not hallucinogenic.⁽⁶⁾ Two people who held 2 g of fermented kougoed in the mouth with a little alcohol described a “tranquil mellowness” after 30 minutes, with no loss of coordination and no hallucinations.⁽⁶⁾

At supplement doses, users commonly describe calm or a mild lift in mood rather than a high. A few users report brighter colours or closed-eye patterns at high doses (anecdotal); these are visual changes, not full hallucinations.

What Are the Recommended Dosages of Kanna?

Kanna has no official recommended dose; the doses tested in people are 8 to 50 mg per day of Zembrin extract, and the right dosage of Kanna for other forms depends on their alkaloid content, which differs many times between products.

1. Human study doses: the lowest dose tested was 8 mg of Zembrin once daily for 3 months,⁽³⁾ and the highest was 50 mg once daily for 6 weeks.⁽¹⁵⁾ Most trials used 25 mg, either once daily for 8 days to 3 months or as a single dose 30 minutes to 2 hours before testing (see the trial table).

2. Animal-to-human equivalents: in depression-model rats, Zembrin at 25 and 50 mg/kg by mouth had antidepressant-like effects.⁽⁷⁾ The body-surface-area formula is HED (mg/kg) = rat dose x 6 / 37. For 25 mg/kg: 25 x 6 / 37 = 4.054 mg/kg, and 4.054 x 70 = 283.8, about 284 mg for a 70 kg adult. For 50 mg/kg: 8.108 mg/kg, and 8.108 x 70 = 567.6, about 568 mg. These are estimated equivalents, not tested doses, and they sit 11 to 23 times above the 25 mg human dose (284 / 25 = 11.4; 568 / 25 = 22.7).

In the 90-day rat toxicity study, the highest dose, 600 mg/kg per day, caused no adverse effects.⁽⁹⁾ Converted the same way, 600 x 6 / 37 = 97.30 mg/kg, and 97.30 x 70 = 6,811 mg for a 70 kg adult, about 136 times the highest human trial dose of 50 mg (6,811 / 50 = 136.2). This is an estimated equivalent from rats, not a tested human dose.

3. Community reports (anecdotal, not studied): the same milligram amount of two products can differ in strength (see Kanna Extract).

Onset, duration and time of day: onset has not been measured in people; users commonly report effects within about 15 to 30 minutes for extracts or kanna held under the tongue and 30 to 60 minutes for swallowed raw plant, lasting 2 to 4 hours (anecdotal). Because users report more stimulation at higher amounts and disturbed sleep with late use, morning or early-afternoon use is the commonly described pattern (anecdotal). A human half-life has not been established; in mice, mesembrine and mesembrenone could be measured after intravenous dosing, but after an oral dose of an enriched extract (75 mg/kg of each alkaloid) their blood levels stayed below the 5 ng/mL detection limit.⁽¹⁷⁾ See how long nootropics last for how onset and half-life compare across compounds.

Daily use: healthy adults took 8 or 25 mg once daily for up to 3 months, both well tolerated apart from the blood-pressure and temperature differences under Side Effects; daily use beyond 3 months has not been studied.

Practices users commonly describe to limit side effects (anecdotal, not studied):

• Using the lowest amount that has an effect, because sensitivity to kanna varies
• Taking it with a little food to reduce nausea, although users report a faster effect on an empty stomach
• Waiting 2 to 3 hours before any repeat amount, because quick re-dosing is reported to cause nausea or dizziness
• Avoiding alcohol and other serotonergic substances
• Using it a few days a week with breaks, to limit tolerance; see how to cycle nootropics

Dosage for Anxiety Management

For situational anxiety, the only regimen tested is a single 25 mg dose of Zembrin, taken about 30 minutes before a simulated speech in the speech-stress study and 2 hours before the scan in the imaging study (see the trial table).

• Ongoing anxiety: daily 25 mg for 3 weeks and 25 or 50 mg for 6 weeks were tested for cognition and brain waves in healthy adults, not as anxiety treatment.
• Generalized anxiety, social anxiety and panic disorder: no dose has been tested; the twice-daily schedules circulating online are anecdotal.

Some people report more anxiety at first, as in the case report of a transient rise during the first week. Anyone using prescribed anxiety or depression medicine needs a doctor’s advice before adding kanna.

What are the Risks and Safety Concerns of Using Kanna?

Kanna’s main risks come from combining it with antidepressants or other serotonergic drugs, from high doses, and from product quality; trial safety data cover healthy adults for up to 3 months (see Side Effects), so longer use, pregnancy and people under 18 are unstudied.

What are the Potential Side Effects and Adverse Reactions to Kanna?

In the 3-month safety trial, 4 of 12 people on 8 mg (33.3%), 7 of 12 on 25 mg (58.3%) and 11 of 13 on placebo (84.6%) reported at least one adverse event, and headache affected 1 of 12, 2 of 12 and 4 of 13.⁽³⁾ With only 12 or 13 people per group, these counts show no excess of side effects with kanna, not that kanna prevents them. Events the investigator judged possibly related to kanna were single cases of constipation, headache and insomnia at 8 mg, and of decreased appetite, muscle spasms, agitation, headache and depressed mood at 25 mg, with one case of irritability judged probably related.⁽³⁾

In the 3-week cognition trial, 2 of 21 people (9.5%) had transient stomach discomfort that resolved on its own.⁽¹³⁾ The 8-day trial of 60 adults recorded no side effects, though fatigue scores were higher with kanna than with placebo (p = 0.023).⁽¹⁴⁾

Side effects named in studies of kanna as a supplement are headache, gastrointestinal problems, fatigue, drowsiness and difficulty concentrating.⁽¹¹⁾ Users also commonly report (anecdotal; frequencies in everyday use are not known):

• Nausea or upset stomach: more often at higher amounts or on an empty stomach
• Dizziness: mainly with first use and quick re-dosing
• Dry mouth
• Dilated pupils and light sensitivity: at high amounts
• Insomnia or a stimulated feeling: with late-day use
• A temporary rise in anxiety or irritability: also seen in a trial participant and a case report (see above)

Liver and blood tests: blood counts and blood chemistry did not change significantly over 3 months at 8 or 25 mg per day.⁽³⁾ People with liver disease should still ask a doctor first, because the liver breaks down kanna’s alkaloids.

Blood pressure and temperature: over 3 months, diastolic pressure rose 1.92 mmHg in the 8 mg group while it fell 6.17 mmHg with placebo, a difference of 8.08 mmHg (95% CI 1.51 to 14.65); the 25 mg group did not differ from placebo.⁽³⁾ Body temperature differed from placebo by 0.47 °C at 8 mg and 0.54 °C at 25 mg (p < 0.05), differences the investigators judged not clinically relevant.⁽³⁾ Blood pressure, pulse and weight did not change in the 3-week trial.⁽¹³⁾

Animal data: rats given 5 or 20 mg/kg per day of an extract of unfermented plant for 17 days showed raised inflammatory markers (C-reactive protein and prostaglandin E2), a pattern consistent with intolerance to the treatment.⁽¹⁸⁾

Long-term vs. Short-term Side Effects:
User-reported side effects are mostly acute and pass within hours (anecdotal); effects of daily use beyond 3 months are unknown. For side effects across supplement classes, see nootropics side effects.

Are There Any Known Contraindications or Drug Interactions with Kanna?

Kanna should not be combined with SSRIs, SNRIs or other serotonin-raising drugs: a review of the plant advises avoiding antidepressants that act on serotonin, including SSRIs such as fluoxetine, sertraline and escitalopram and SNRIs such as duloxetine and venlafaxine, although no severe herb-drug interactions had been reported by 2021.⁽⁵⁾ The cautions:

• MAO inhibitors (MAOIs, such as phenelzine, tranylcypromine or selegiline): avoid, including within 2 weeks of the last MAOI dose; ask a pharmacist or doctor. The combination would risk serotonin syndrome (inferred from kanna’s serotonin-reuptake action).
• SSRIs, SNRIs, tricyclic antidepressants (such as amitriptyline), triptans for migraine and St. John’s wort: avoid; ask a pharmacist or doctor. Other serotonergic substances such as 5-HTP, tramadol and MDMA would add to the same effect (inferred), with a risk of agitation, tremor and overheating.
• Antipsychotics and other psychiatric medicines: ask a doctor first.
• Other PDE4 inhibitors: the COPD drug roflumilast and the plant flavonoid luteolin also inhibit PDE4,⁽⁵⁾ so combining them with kanna could add to the same pathway (inferred); ask a pharmacist or doctor.
• Drugs metabolized by liver enzymes: in human liver preparations, mesembrine was broken down by CYP1A2, CYP2B6, CYP2C19, CYP2D6, CYP3A4 and CYP3A5 enzymes, and the clinical significance of this is not yet known;⁽⁵⁾ people on medicines with a narrow dose range should ask a pharmacist.
• Sedatives (benzodiazepines, sleeping pills, muscle relaxers), alcohol and cannabis: ask a pharmacist or doctor; data on combined sedation are lacking, and recreational use of kanna with cannabis or other psychoactive agents is a specific safety concern.⁽¹¹⁾
• Blood thinners and scheduled surgery: no interaction with anticoagulants or antiplatelet drugs has been studied; stopping kanna 2 weeks before scheduled surgery is a common precaution for psychoactive herbs.
• Thyroid, blood-pressure and diabetes medicines: no specific interaction is established, and kanna has not been studied with them; ask a pharmacist or doctor first. The diastolic difference at 8 mg (see Side Effects) is a reason to check blood pressure.
• Pregnancy and breastfeeding: avoid, because safety has not been studied; the 3-month safety trial enrolled only non-pregnant adults aged 18 to 55.⁽³⁾
• Children and teenagers under 18: not studied and not recommended.
• Bipolar disorder, a history of mania, psychosis, hallucinations, paranoia or a past suicide attempt: avoid unless a psychiatrist approves; serotonergic agents would risk triggering mania (inferred).
• Liver or kidney disease: ask a doctor first.
• Allergy: avoid if allergic to kanna or other ingredients; get help at once with swelling of the face or throat, wheezing, hives or fainting.
• History of substance misuse: ask a doctor; recreational use of kanna is a known pattern.

Does Kanna Pose a Risk of Dependence or Addiction?

Kanna has shown a low addiction risk in the available data: in rats, kanna extract injected at 25, 50 and 100 mg/kg did not cause conditioned place preference, a standard test of whether a drug is rewarding.⁽¹⁶⁾ Chronic use does not appear to cause a withdrawal state, and one case-report patient stopped after 4 months of continual use with no withdrawal signs.⁽⁶⁾

Users commonly report tolerance with frequent high-dose use, and some describe these symptoms after stopping heavy use; these reports are anecdotal, and reports differ:

• Irritability
• Low mood
• Sleep disturbances
• Cravings
• Headaches

What are the Signs of Kanna Abuse or Overdose?

A large kanna dose causes intoxication rather than a known fatal toxicity: in a 1914 self-experiment, chewing 5 g of kougoed caused nausea, numbness in the mouth, head discomfort and loss of appetite, and 15 g swallowed as a decoction added headache.⁽⁶⁾ The more serious risk is serotonin toxicity (serotonin syndrome) when kanna is combined with other serotonergic drugs, inferred from its serotonin-reuptake action. Its signs include:

• Agitation
• Tremors
• Muscle rigidity
• Hyperthermia
• Rapid heartbeat
• High blood pressure
• Seizures
• Coma

If serotonin syndrome is suspected, seek emergency medical attention immediately.

Is Kanna Legal?

In most of the US, kanna is sold as a dietary supplement ingredient; it is not on the Department of Defense Prohibited Dietary Supplement Ingredients List, but service-specific policies still prohibit any substance used to get high or alter the state of mind.⁽¹¹⁾ Kanna is not FDA-approved to treat anxiety or depression.

Louisiana is an exception: its hallucinogenic-plant law lists the genus Mesembryanthemum, under which kanna is also classified, and makes it a crime to produce or distribute (2 to 10 years in prison) or possess (up to 5 years) a preparation for human consumption that contains such a plant, except a product labelled as a dietary supplement and made in compliance with federal Food, Drug, and Cosmetic Act requirements.⁽¹⁹⁾

In the UK, the Psychoactive Substances Act 2016 makes it an offence to supply a psychoactive substance for its psychoactive effects,⁽²⁰⁾ while controlled drugs, medicinal products, caffeine and ordinary food are exempt.⁽²¹⁾ Kanna is not among these exemptions, so supplying it in the UK for its effects on mood is likely to fall under the supply offence (a reading of the Act, not a court ruling). Its offences are producing, supplying or offering to supply, possessing with intent to supply, importing or exporting, and possessing a psychoactive substance in a custodial institution; possession for personal use elsewhere is not among them.⁽²²⁾

Product quality: some kanna supplements have been reported adulterated with hordenine and ephedrine, both on the DoD prohibited list, and buyers are advised to check whether a label has been evaluated by an independent third-party organization; Zembrin is a trademarked standardized extract often named on labels.⁽¹¹⁾

Drug tests: mesembrine and mesembrenone metabolites were identified in rat urine with the authors’ standard urine screening approaches (GC-MS or LC-MS), and most also formed in human liver preparations, so a laboratory looking for kanna could detect its use, assuming the alkaloids are handled the same way in people.⁽²³⁾ Routine workplace drug panels look for other drug classes and are not designed for kanna alkaloids (inferred).

How Does Kanna Compare to Other Nootropics?

Kanna and St. John’s wort both act on serotonin reuptake, while the other supplements in the table below act through other pathways, so kanna has a more direct interaction with antidepressants than most of them:

Kanna matches the goal of calmer stress responses before a demanding event, the use tested in its single-dose trials, and does not suit anyone on an antidepressant or with bipolar disorder.

Can Kanna Be Combined with Other Nootropics for Enhanced Effects?

No kanna combination has been tested in a trial, so any synergy is inferred from each compound’s separate effects. Users pair kanna with nootropics that do not act on serotonin, such as L-theanine, gotu kola and small amounts of caffeine (no interaction data), and avoid 5-HTP, St. John’s wort, SAMe and other serotonergic supplements as well as strong sedatives such as phenibut or high-dose kava. Example stacks follow.

Kanna’s Role in Nootropic Stacks

Kanna’s role in a stack is the calm-and-mood component: its tested benefits sit in stress response and executive function rather than memory.

Kanna in Common Nootropic Stacks (anecdotal combinations; none has been tested as a stack):

• Focus and Mood Stack: Kanna extract (15-25 mg) with L-Theanine (200 mg) and a low dose of caffeine (50-100 mg), a combination users describe for focus without the jitteriness caffeine alone can cause (anecdotal).
• Memory Enhancement Stack: Kanna extract (20 mg) paired with Bacopa Monnieri (300 mg) and Lion’s Mane (500-1000 mg), a combination users describe for memory support (anecdotal).
• Anxiety-Free Productivity Stack: Kanna extract (25 mg) with Ashwagandha (300 mg) and Rhodiola Rosea (200 mg), a combination users describe for performance under stress (anecdotal).

Kanna is not a classic stimulant, and jitteriness is not a typical user report (anecdotal; for insomnia see Side Effects); a natural origin does not remove side effects, and its serotonin action brings the interaction risks under Contraindications. See nootropic stacks for how stacks are built and types of nootropics for where herbal nootropics sit among other classes.

1. Harvey, Alan L et al. “Pharmacological actions of the South African medicinal and functional food plant Sceletium tortuosum and its principal alkaloids.” Journal of ethnopharmacology vol. 137,3 (2011): 1124-9. doi:10.1016/j.jep.2011.07.035↩↩↩↩
2. Terburg, David et al. “Acute effects of Sceletium tortuosum (Zembrin), a dual 5-HT reuptake and PDE4 inhibitor, in the human amygdala and its connection to the hypothalamus.” Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology vol. 38,13 (2013): 2708-16. doi:10.1038/npp.2013.183↩↩↩↩
3. Nell, Haylene et al. “A randomized, double-blind, parallel-group, placebo-controlled trial of Extract Sceletium tortuosum (Zembrin) in healthy adults.” Journal of alternative and complementary medicine (New York, N.Y.) vol. 19,11 (2013): 898-904. doi:10.1089/acm.2012.0185↩↩↩↩↩↩↩↩↩↩
4. Gouhie, Felipe Araujo et al. “Sceletium tortuosum effects on anxiety: A systematic review and meta-analysis.” Brain Disorders vol. 11 (2023): 100092. doi:10.1016/j.dscb.2023.100092↩↩
5. Brendler, Thomas et al. “Sceletium for Managing Anxiety, Depression and Cognitive Impairment: A Traditional Herbal Medicine in Modern-Day Regulatory Systems.” Current neuropharmacology vol. 19,9 (2021): 1384-1400. doi:10.2174/1570159X19666210215124737↩↩↩↩↩↩↩
6. Gericke, N, and A M Viljoen. “Sceletium–a review update.” Journal of ethnopharmacology vol. 119,3 (2008): 653-63. doi:10.1016/j.jep.2008.07.043↩↩↩↩↩↩↩↩↩↩
7. Gericke, Johané et al. “An acute dose-ranging evaluation of the antidepressant properties of Sceletium tortuosum (Zembrin®) versus escitalopram in the Flinders Sensitive Line rat.” Journal of ethnopharmacology vol. 284 (2022): 114550. doi:10.1016/j.jep.2021.114550↩↩↩
8. National Center for Biotechnology Information. “PubChem Compound Summary for CID 394162, Mesembrine.” PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/394162↩
9. Murbach, Timothy S et al. “A toxicological safety assessment of a standardized extract of Sceletium tortuosum (Zembrin®) in rats.” Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association vol. 74 (2014): 190-9. doi:10.1016/j.fct.2014.09.017↩↩
10. Patnala, Srinivas, and Isadore Kanfer. “Investigations of the phytochemical content of Sceletium tortuosum following the preparation of ‘Kougoed’ by fermentation of plant material.” Journal of ethnopharmacology vol. 121,1 (2009): 86-91. doi:10.1016/j.jep.2008.10.008↩↩
11. Operation Supplement Safety. “Kanna: Uses and Safety in Dietary Supplements.” OPSS, 15 Dec. 2025, https://www.opss.org/article/kanna-uses-and-safety-dietary-supplements↩↩↩↩↩↩
12. Reay, Jonathon et al. “Sceletium tortuosum (Zembrin®) ameliorates experimentally induced anxiety in healthy volunteers.” Human psychopharmacology vol. 35,6 (2020): 1-7. doi:10.1002/hup.2753↩↩↩
13. Chiu, Simon et al. “Proof-of-Concept Randomized Controlled Study of Cognition Effects of the Proprietary Extract Sceletium tortuosum (Zembrin) Targeting Phosphodiesterase-4 in Cognitively Healthy Subjects: Implications for Alzheimer’s Dementia.” Evidence-based complementary and alternative medicine : eCAM vol. 2014 (2014): 682014. doi:10.1155/2014/682014↩↩↩↩↩↩↩↩
14. Hoffman, Jay R et al. “Ergogenic Effects of 8 Days of Sceletium Tortuosum Supplementation on Mood, Visual Tracking, and Reaction in Recreationally Trained Men and Women.” Journal of strength and conditioning research vol. 34,9 (2020): 2476-2481. doi:10.1519/JSC.0000000000003693↩↩↩
15. Dimpfel, Wilfried et al. “Effect of Zembrin® on Brain Electrical Activity in 60 Older Subjects after 6 Weeks of Daily Intake. A Prospective, Randomized, Double-Blind, Placebo-Controlled, 3-Armed Study in a Parallel Design.” World Journal of Neuroscience vol. 7,1 (2017): 140-171. doi:10.4236/wjns.2017.71011↩↩↩
16. Loria, Melissa J et al. “Effects of Sceletium tortuosum in rats.” Journal of ethnopharmacology vol. 155,1 (2014): 731-5. doi:10.1016/j.jep.2014.06.007↩↩
17. Manda, Vamshi K et al. “Quantification of mesembrine and mesembrenone in mouse plasma using UHPLC-QToF-MS: Application to a pharmacokinetic study.” Biomedical chromatography : BMC vol. 31,3 (2017): 10.1002/bmc.3815. doi:10.1002/bmc.3815↩
18. Smith, C. “The effects of Sceletium tortuosum in an in vivo model of psychological stress.” Journal of ethnopharmacology vol. 133,1 (2011): 31-6. doi:10.1016/j.jep.2010.08.058↩
19. Louisiana State Legislature. “RS 40:989.1, Unlawful production, manufacture, distribution, or possession of hallucinogenic plants; exceptions.” legis.la.gov, https://legis.la.gov/Legis/Law.aspx?d=321523↩
20. UK Parliament. “Psychoactive Substances Act 2016, section 5.” legislation.gov.uk, https://www.legislation.gov.uk/ukpga/2016/2/section/5↩
21. UK Parliament. “Psychoactive Substances Act 2016, Schedule 1.” legislation.gov.uk, https://www.legislation.gov.uk/ukpga/2016/2/schedule/1↩
22. UK Parliament. “Psychoactive Substances Act 2016, contents.” legislation.gov.uk, https://www.legislation.gov.uk/ukpga/2016/2/contents↩
23. Meyer, Golo M J et al. “GC-MS, LC-MS(n), LC-high resolution-MS(n), and NMR studies on the metabolism and toxicological detection of mesembrine and mesembrenone, the main alkaloids of the legal high ‘Kanna’ isolated from Sceletium tortuosum.” Analytical and bioanalytical chemistry vol. 407,3 (2015): 761-78. doi:10.1007/s00216-014-8109-9↩